SE9302203L - Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning - Google Patents

Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning

Info

Publication number
SE9302203L
SE9302203L SE9302203A SE9302203A SE9302203L SE 9302203 L SE9302203 L SE 9302203L SE 9302203 A SE9302203 A SE 9302203A SE 9302203 A SE9302203 A SE 9302203A SE 9302203 L SE9302203 L SE 9302203L
Authority
SE
Sweden
Prior art keywords
eye
composition
aqueous solution
topical administration
acid diesters
Prior art date
Application number
SE9302203A
Other languages
English (en)
Other versions
SE501482C2 (sv
SE9302203D0 (sv
Inventor
Arto Urtti
Tomi Jaervinen
Pekka Suhonen
Kari Lehmussaari
Timo Reunamaeki
Sakari Alaranta
Olli Oksala
Esko Pohjala
Hannu Hanhijaervi
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Priority to SE9302203A priority Critical patent/SE501482C2/sv
Publication of SE9302203D0 publication Critical patent/SE9302203D0/sv
Priority to PCT/FI1994/000270 priority patent/WO1995000144A1/en
Priority to AU69731/94A priority patent/AU6973194A/en
Priority to LTIP1970A priority patent/LT3525B/lt
Priority to EE9400040A priority patent/EE9400040A/xx
Publication of SE9302203L publication Critical patent/SE9302203L/sv
Publication of SE501482C2 publication Critical patent/SE501482C2/sv

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9302203A 1993-06-24 1993-06-24 Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning SE501482C2 (sv)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE9302203A SE501482C2 (sv) 1993-06-24 1993-06-24 Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
PCT/FI1994/000270 WO1995000144A1 (en) 1993-06-24 1994-06-17 Composition for ophthalmic use
AU69731/94A AU6973194A (en) 1993-06-24 1994-06-17 Composition for ophthalmic use
LTIP1970A LT3525B (en) 1993-06-24 1994-06-23 Composition for ophthalmic use
EE9400040A EE9400040A (et) 1993-06-24 1994-08-18 Oftalmiliseks otstarbeks mõeldud kompositsioon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9302203A SE501482C2 (sv) 1993-06-24 1993-06-24 Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning

Publications (3)

Publication Number Publication Date
SE9302203D0 SE9302203D0 (sv) 1993-06-24
SE9302203L true SE9302203L (sv) 1994-12-25
SE501482C2 SE501482C2 (sv) 1995-02-27

Family

ID=20390417

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9302203A SE501482C2 (sv) 1993-06-24 1993-06-24 Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning

Country Status (5)

Country Link
AU (1) AU6973194A (sv)
EE (1) EE9400040A (sv)
LT (1) LT3525B (sv)
SE (1) SE501482C2 (sv)
WO (1) WO1995000144A1 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001558A1 (en) * 1994-07-11 1996-01-25 Pate David W Anandamide analogue compositions and method of treating intraocular hypertention using same
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
EP4247340A4 (en) 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
US20250345458A1 (en) * 2022-05-18 2025-11-13 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
TW200402B (sv) * 1990-08-13 1993-02-21 Senju Pharma Co
FI98815C (sv) * 1990-11-30 1997-08-25 Santen Oy Förfarande för framställning av nya farmakologiskt användbara esterderivat av bispilokarpinsyra

Also Published As

Publication number Publication date
SE501482C2 (sv) 1995-02-27
LTIP1970A (en) 1995-01-31
EE9400040A (et) 1995-12-15
LT3525B (en) 1995-11-27
SE9302203D0 (sv) 1993-06-24
WO1995000144A1 (en) 1995-01-05
AU6973194A (en) 1995-01-17

Similar Documents

Publication Publication Date Title
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
ATE210943T1 (de) Ophthalmologisches abgabesystem
WO2002045662A3 (en) Anhydrous creams, lotions and gels
MEP10408A (en) Platinum derivative pharmaceutical formulations
AU532114B2 (en) Salts of n-substituted-2-pyrrolidone-4-carboxylic acids
SE8305485D0 (sv) Galenic compositions comprising calcitonin and their use
BR0307893A (pt) Formulação oftálmica com sistema de goma
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
AU9163701A (en) Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
NO20030411L (no) Farmasöytiske sammensetninger for behandlingen av smertefulle, inflammatoriske og ulceröse tilstander av fuktige epiteloverflater slik sommukositt, stomatitt og Behcets syndrom
NO970051L (no) Vandige risperidon formuleringer
ES2107832T3 (es) Una composicion farmaceutica para la administracion intranasal de hidroxocobalamina.
DK0562512T3 (da) Sulfonamidocarbonylpyridin-2-carboxylsyreamider samt deres anvendelse som lægemidler
ATE170194T1 (de) Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
EP1354602A4 (en) MEDICAL COMPOSITIONS WITH DIURETIC AGENT AND IMPROVING INSULIN RESISTANCE
SE9302203D0 (sv) Composition for ophthalmic use
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
WO2002056840A3 (de) Kosmetisches und/oder pharmazeutisches mittel acylierte aminosaüre enthaltend.
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
DE60003074D1 (de) Fusidinsäure-derivate
ES2032572T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica para aplicacion topica sobre la piel.
ES2156877T3 (es) Anilidas de acidos cicloalquilcarboxilicos.
PT1305033E (pt) Composicoes farmaceuticas que contem tobramicina e goma de xantano